01 August 2012: Review Article
Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
George B. Stefano , Kirk J. Mantione , Milena Králíčková , Radek Ptacek , Hana Kuzelova , Tobias Esch , Richard M. Kream
DOI: 10.12659/MSM.883259
Med Sci Monit 2012; 18(8): RA133-137
Background
The discipline of endogenous morphine research has experienced a prolonged gestational period of nearly four decades, often marked by skepticism and prejudicial disregard from a significant portion of the scientific community. Within the last decade, however, a wealth of complementary biochemical, molecular, and physiological studies emanating from major independent laboratories has provided indispensable self-validating, foundation data sets to solidify the status of endogenous morphine research as a vital component of the biological sciences. Briefly, indisputable Q-TOF tandem mass spectrometry has confirmed the presence of low steady-state levels of chemically authentic morphine in diverse animal cells and organ systems [1–12]. Biochemical studies have characterized multiple enzyme-catalyzed reactions and chemically defined intermediate precursor molecules within a regulated biosynthetic pathway that display striking similarities to the plant biosynthetic scheme previously established in Papaver somniferum [1–35]. Preclinical and clinical studies have demonstrated regulated expression of endogenous morphine upon physiological demand in normative regulatory processes and in dysregulatory disease states [2–35]. As a unifying principle, our laboratory has identified and characterized a cellular “morphinergic” signaling pathway functionally linked to constitutive nitric oxide production and mediated by cognate mu3 and mu4 opiate receptors [13,18,22,36,37].
In light of the above, we engage the privilege of historical hindsight to propose that clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson’s Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system (CNS) dopamine (DA) neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling
Urinary Excretion of Morphine, Codeine, and Tetrahydropapaveroline by Parkinson’s Disease Patients: Presumptive Evidence for L-DOPA as a Morphine Precursor
It is twenty years since the publication of a clinical report indicating an approximate 20 fold enrichment of morphine, codeine, and the benzylisoquinoline (BIQ) alkaloid tetrahydropapaveroline (THP, also called norlaudanosoline) in the urine of Parkinson’s disease (PD) patients receiving L-DOPA replacement therapy, as compared to naive healthy controls [38]. The study was closely followed by a 1993 case report that quantified THP concentrations in the urine of 3 PD patients treated with L-DOPA-Carbidopa formulated as Sinemet [39]. In confirmation of the earlier report, the second study demonstrated marked increases in urinary THP concentrations that were roughly correlated with low, medium, and high administered dosages of L-DOPA-Carbidopa. These collected results provide putative evidence that endogenous morphine and codeine are synthesized
Biological Signficance of Tetrahydropapaveroline as a Peripherally Expressed Morphine Precursor
Interestingly, the reports cited above are also confirmatory of a 1987 preclinical study demonstrating dramatic increases in rat brain concentrations of THP subsequent to peripheral co-administration of L-DOPA and ethanol [44]. Despite an excessively high concentration of ethanol (3 g/kg) that was administrated via the intraperitoneal route, it is apparent that a rapid synthesis of THP was accomplished over a 1–2 hour time frame. A first approximation of the rate of conversion of administered L-DOPA to THP yielded a value of approximately 0.1%. Of equal importance, a compartmental model emerges whereby THP is rapidly synthesized at peripheral sites, followed by rapid blood brain barrier transport into the CNS [45].
At this time, a cogent mechanism of peripheral THP biosynthesis in the presence or absence of ethanol has not been elucidated. Retrospectively, the contention of prominent scientists in alcohol addiction research that THP represents an aberrant and biologically deleterious DA derivative [40,42,46–52] that is markedly enhanced by ethanol, an ethanol metabolite such as acetaldehyde, or an enzyme involved in ethanol metabolism, i.e., acetaldehyde dehydrogenase appears to be critically flawed by the presence of THP in the urine of healthy, alcohol naïve, subjects [38]. Furthermore, the reluctance of alcoholism researchers to embrace THP as a naturally occuring morphine precursor is saliently at odds with preclinical studies demonstrating marked reductions of alcohol intake by opiate antagonists such as naloxone and naltrexone [53,54] and widespread clinical employment of naltrexone as a frontline pharmacotherapy for treatment of alcohol dependence [55].
In contrast to alcoholism research, there appeared to be a greater depth of critical thinking among PD researchers that pertained to positive and negative biological effects of THP and related tetrahydroisoquinoline alkaloids subsequent to L-DOPA administration. Despite a series of preclinical studies drawing a functional association between aberrant DA metabolism, cellular expression of THP and related tetrahydroisoquinoline alkaloids, and the etiology of PD [38,41,52,56–76], select clinical studies were supportive of positive therapeutic effects of pharmacologically administered morphine for treatment of PD dyskinesias [75,76]. Of potentially greater significance, a small body of biochemical and pharmacological studies demonstrated normative expression of THP and related tetrahydroisoquinoline alkaloids within the adrenal medulla and their associated regulatory activities on catecholamine synthetic and metabolic enzymes [57,68].
Spector’s laboratory was the first to quantify relatively high concentrations of chemically authentic morphine and codeine in rat adrenal gland [77]. Interestingly, levels of the penultimate morphine precursor codeine were found to be greater than those of morphine, suggesting a precursor to product biosynthetic relationship of the two opiate alkaloids in this glandular tissue. Relatively recently, our group has provided extensive empirical evidence supporting the role of the adrenal medulla as a major pheripheral site of endogenous morphine expression and physiological “hot spot” for opiate regulation of adrenergic sympethetic activities [2,4–7,9].
Based on the collective complementary lines of evidence presented above, we propose that restorative L-DOPA therapy for chronic management of PD patients represents an
Conclusions
Historically, the identification of THP as a biologically active Pictet-Spengler condensation product of DA and 3,4-dihydroxyphenylacetaldehyde (DOPAL) preceded the identification of low steady-state levels of immunologically detectable morphine in several species of mammalian brain [81,82]. A similar enzymatic step in Papaver somniferum is mediated by the biosynthetic enzyme nococlaurine synthase that catalyzes an asymmetric Pictet-Spengler condensation of DA and 4-hydroxyphenylacetaldehyde to yield (S)-norcoclaurine, the plant equivalent of THP [83] (Figure 1).
Morphine, DA, and catecholamine synthesis and metabolism share a similar set of L-Tyrosine-related substrates and enzymes activities. The role of endogenous morphine as an evolutionary model in the adaptation and maintenance of DA and catecholamines as predominant signaling molecules in relatively simple and complex nervous/CNS structures defines its biological presence as an autocrine/paracrine regulator of cellular homeostasis [36,37,84–86]. The biological activities underlying endogenous morphine expression and its interaction with its major precursor DA strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD [87,88].
References
1. Boettcher C, Fellermeier M, Boettcher C, How human neuroblastoma cells make morphine: Proc Natl Acad Sci USA, 2005; 102; 8495-500, pmid: 15937106
2. Goumon Y, Bouret S, Casares F, Lipopolysaccharide increases endogenous morphine levels in rat brain: Neuroscience Letters, 2000; 293; 135-38, pmid: 11027852
3. Goumon Y, Casares F, Pryor S, Ascaris suum, an internal parasite, produces morphine: J Immunol, 2000; 165; 339-43, pmid: 10861070
4. Goumon Y, Weeks BS, Cadet P, Stefano GB, Identification of morphine in the adrenal medullary chromaffin PC-12 cell line: Mol Brain Res, 2000; 81; 177-80, pmid: 11000489
5. Goumon Y, Casares F, Zhu W, Stefano GB, The presence of morphine in ganglionic tissues of Modiolus deminissus: A highly sensitive method of quantitation for morphine and its derivatives: Mol Brain Res, 2001; 86; 184-88, pmid: 11165385
6. Goumon Y, Strub JM, Stefano GB, Characterization of a morphine-like molecule in secretory granules of chromaffin cells: Med Sci Monit, 2005; 11(5); MS31-34, pmid: 15874897
7. Goumon Y, Stefano GB, Identification of morphine in the rat adrenal gland: Mol Brain Res, 2000; 77; 267-69, pmid: 10837921
8. Zhu W, Baggerman G, Goumon Y, Presence of morphine and morphine-6-glucuronide in the marine mollusk Mytilus edulis ganglia determined by GC/MS and Q-TOF-MS. Starvation increases opiate alkaloid levels: Brain Res Mol Brain Res, 2001; 88; 155-60, pmid: 11295241
9. Zhu W, Baggerman G, Goumon Y, Identification of morphine and morphine-6-glucuronide in the adrenal medullary chromaffin PC-12 cell line by nano electrospray ionization double quadrupole orthogonal acceleration time of flight mass spectrometry: Eur J of Mass Spect, 2001; 7; 25-28
10. Zhu W, Baggerman G, Secor WE, Dracunculus medinensis and Schistosoma mansoni contain opiate alkaloids: Ann Trop Med Parasitol, 2002; 96; 309-16, pmid: 12061977
11. Zhu W, Bilfinger TV, Baggerman G, Presence of endogenous morphine and morphine 6 glucuronide in human heart tissue: Int J Mol Med, 2001; 7; 419-22, pmid: 11254885
12. Zhu W, Ma Y, Stefano GB, Presence of isoquinoline alkaloids in molluscan ganglia: Neuroendocrinol Lett, 2002; 23; 329-34, pmid: 12195236
13. Stefano GB, Digenis A, Spector S, Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression: Proc Natl Acad Sci USA, 1993; 90; 11099-103, pmid: 8248214
14. Brix-Christensen V, Goumon Y, Tonnesen E, Endogenous morphine is produced in response to cardiopulmonary bypass in neonatal pigs: Acta Anaesthesiol Scand, 2000; 44; 1204-8, pmid: 11065199
15. Guarna M, Bianchi E, Bartolini A, Endogenous morphine modulates acute thermonociception in mice: J Neurochem, 2002; 80; 271-77, pmid: 11902117
16. Stefano GB, Zhu W, Cadet P, A hormonal role for endogenous opiate alkaloids: Vascular tissues: Neuro Endocrinol Lett, 2002; 23; 21-26, pmid: 11880858
17. Guarna M, Bartolini A, Ghelardini C, Anti-mu opioid antiserum against the third external loop of the cloned mu opioid receptor acts a mu receptor neutral antagonist: Mol Brain Res, 2003; 119; 100-10, pmid: 14597234
18. Cadet P, Mantione KJ, Stefano GB, Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene: J Immunol, 2003; 170; 5118-23, pmid: 12734358
19. Stefano GB, Cadet P, Rialas CM, Invertebrate Opiate Immune and Neural Signaling: Immune Mechanisms of Pain and Analgesia, 2003; 126-47, New York, NY, Plenum Publ
20. Zhu W, Ma Y, Cadet P, Presence of reticuline in rat brain: A pathway for morphine biosynthesis: Mol Brain Res, 2003; 117; 83-90, pmid: 14499484
21. Cadet P, Rasmussen M, Zhu W, Endogenous morphinergic signaling and tumor growth: Front Biosci, 2004; 9; 3176-86, pmid: 15353348
22. Stefano GB, Zhu W, Cadet P, Mantione K, Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the m3 opiate receptor subtype: A hormonal role for endogenous morphine: J Physiol Pharmacol, 2004; 55; 279-88, pmid: 15082884
23. Stefano GB, Zhu W, Cadet P, Music alters constitutively expressed opiate and cytokine processes in listeners: Med Sci Monit, 2004; 10(6); MS18-27, pmid: 15173680
24. Zhu W, Pryor SC, Putnam J: J Parasitol, 2004; 90; 15-22, pmid: 15040662
25. Zhu W, Ma Y, Bell A, Presence of morphine in rat amygdala: Evidence for the mu3 opiate receptor subtype via nitric oxide release in limbic structures: Med Sci Monit, 2004; 10(12); BR433-39, pmid: 15567973
26. Zhu W, Stefano GB, Reticuline exposure to invertebrate ganglia increases endogenous morphine levels: Neuro Endocrinol Lett, 2004; 25; 323-30, pmid: 15580165
27. Casares FM, McElroy A, Mantione KJ, The American lobster, Homarus americanus, contains morphine that is coupled to nitric oxide release in its nervous and immune tissues: Evidence for neurotransmitter and hormonal signaling: Neuro Endocrinol Lett, 2005; 26; 89-97, pmid: 15855878
28. Zhu W, Mantione KJ, Shen L, Stefano GB: Med Sci Monit, 2005; 11(5); MS1-5, pmid: 15874894
29. Zhu W, Mantione KJ, Shen L: Med Sci Monit, 2005; 11(11); BR397-404, pmid: 16258388
30. Zhu W, Cadet P, Baggerman G, Human white blood cells synthesize morphine: CYP2D6 modulation: J Immunol, 2005; 175; 7357-62, pmid: 16301642
31. Dusek JA, Chang BH, Zaki J, Association between oxygen consumption and nitric oxide production during the relaxation response: Med Sci Monit, 2006; 12(1); CR1-10, pmid: 16369463
32. Zhu W, Mantione K, Kream RM, Stefano GB, Alcohol-, Nicotine-, and Cocaine-Evoked Release of Morphine from Human White Blood Cells: Substances of Abuse Actions Converge on: Endogenous Morphine Release Med Sci Monit, 2006; 12(11); BR350-54
33. Zhu W, Mantione KJ, Casares FM, Alcohol-, nicotine-, and cocaine-evoked release of morphine from invertebrate ganglia: Model system for screening drugs of abuse: Med Sci Monit, 2006; 12(5); BR155-61, pmid: 16641868
34. Zhu W, Cadet P, Mantione KJ, Response to Comment on “Human White Blood Cells Synthesize Morphine: CYP2D6 Modulation”: J Immunol, 2006; 176; 5704
35. Zhu W, Mantione KJ, Casares FM, Cholinergic regulation of endogenous morphine release from lobster nerve cord: Med Sci Monit, 2006; 12(9); BR295-301, pmid: 16940924
36. Cadet P, Mantione KJ, Zhu W, A functionally coupled mu3-like opiate receptor/nitric oxide regulatory pathway in human multi-lineage progenitor cells: J Immunol, 2007; 179; 5839-44, pmid: 17947657
37. Kream RM, Sheehan M, Cadet P, Persistence of evolutionary memory: Primordial six-transmembrane helical domain mu opiate receptors selectively linked to endogenous morphine signaling: Med Sci Monit, 2007; 13(12); SC5-6, pmid: 18049446
38. Matsubara K, Fukushima S, Akane A, Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans: J Pharmacol Exp Ther, 1992; 260; 974-78, pmid: 1545408
39. Cashaw JL, Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography: J Chromatogr, 1993; 613; 267-73, pmid: 8491812
40. Walsh MJ, Davis VE, Yamanaka Y: J Pharmacol Exp Ther, 1970; 174; 388-400, pmid: 4318487
41. Sandler M, Carter SB, Hunter KR, Stern GM: Nature, 1973; 241; 439-43, pmid: 4705752
42. Weiner H, Relationship between 3,4-dihydroxyphenylacetaldehyde levels and tetrahydropapaveroline formation: Alcohol Clin Exp Res, 1978; 2; 127-31, pmid: 350075
43. Sango K, Maruyama W, Matsubara K, Enantio-selective occurrence of (S)-tetrahydropapaveroline in human brain: Neurosci Lett, 2000; 283; 224-26, pmid: 10754228
44. Cashaw JL, Geraghty CA, McLaughlin BR, Davis VE, Effect of acute ethanol administration on brain levels of tetrahydropapaveroline in L-dopa-treated rats: J Neurosci Res, 1987; 18; 497-503, pmid: 3125342
45. Cashaw JL, Geraghty CA, Tetrahydropapaveroline and the blood-brain barrier in rats: Alcohol, 1991; 8; 317-19, pmid: 1872993
46. Clow A, Stolerman IP, Murray RM, Sandler M, Ethanol preference in rats: increased consumption after intraventricular administration of tetrahydropapaveroline: Neuropharmacology, 1983; 22; 563-65, pmid: 6856052
47. Duncan CC, Fernando PW, Effects of tetrahydropapaveroline in the nucleus accumbens and the ventral tegmental area on ethanol preference in the rat: Alcohol, 1991; 8; 87-90, pmid: 2064757
48. Halushka PV, Hoffmann PC, Davis VE, Walsh MJ, Alcohol addiction and tetrahydropapaveroline: Science, 1970; 169; 1104-6, pmid: 5465178
49. Myers RD, Anatomical “circuitry” in the brain mediating alcohol drinking revealed by THP-reactive sites in the limbic system: Alcohol, 1990; 7; 449-59, pmid: 2222848
50. Myers RD, Robinson DE, Tetrahydropapaveroline injected in the ventral tegmental area shifts dopamine efflux differentially in the shell and core of nucleus accumbens in high-ethanol-preferring (HEP) rats: Alcohol, 1999; 18; 83-90, pmid: 10386670
51. Sallstrom BS, Hill R, Kiianmaa K, Rommelspacher H, Effect of ethanol on (R)- and (S)-salsolinol, salsoline, and THP in the nucleus accumbens of AA and ANA rats: Alcohol, 1999; 18; 165-69, pmid: 10456568
52. Sandler M, Glover V, Armando I, Clow A, Pictet-Spengler condensation products, stress and alcoholism: some clinical overtones: Prog Clin Biol Res, 1982; 90; 215-26, pmid: 7111321
53. Myers RD, Critcher EC, Naloxone alters alcohol drinking induced in the rat by tetrahydropapaveroline (THP) infused ICV: Pharmacol Biochem Behav, 1982; 16; 827-36, pmid: 6283568
54. Herz A, Endogenous opioid systems and alcohol addiction: Psychopharmacology (Berl), 1997; 129; 99-111, pmid: 9040115
55. Ray LA, Chin PF, Miotto K, Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics: CNS Neurol Disord Drug Targets, 2010; 9; 13-22, pmid: 20201811
56. Heikkila R, Cohen G, Dembiec D, Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake: J Pharmacol Exp Ther, 1971; 179; 250-58, pmid: 5133601
57. Greenberg RS, Cohen G, Tetrahydroisoquinoline alkaloids: stimulated secretion from the adrenal medulla: J Pharmacol Exp Ther, 1973; 184; 119-28, pmid: 4686001
58. Katz S, Cohen G, A comparison of 6,7-dihydroxytetrahydroisoquinoline, salsolinol and tetrahydropapaveroline as inhibitors of monoamine oxidase within the adrenergic nerve plexus of the isolated mouse atrium: Res Commun Chem Pathol Pharmacol, 1976; 13; 217-24, pmid: 1257609
59. Britton DR, A convergent approach to the pharmacology of tetrahydroisoquinolines: Prog Clin Biol Res, 1982; 90; 321-26, pmid: 6287494
60. Suzuki K, Mizuno Y, Yoshida M, Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain: Neurochem Res, 1990; 15; 705-10, pmid: 1975653
61. Niwa T, Maruyama W, Nakahara D: J Chromatogr, 1992; 578; 109-15, pmid: 1400775
62. Naoi M, Maruyama W, Kasamatsu T, Dostert P, Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines: J Neural Transm Suppl, 1998; 52; 125-38, pmid: 9564615
63. Collins MA, Tetrahydropapaveroline in Parkinson’s disease and alcoholism: a look back in honor of Merton Sandler: Neurotoxicology, 2004; 25; 117-20, pmid: 14697886
64. Johnston GA, L-dopa and pyridoxal 5′-phosphate: tetrahydroisoquinoline formation: Lancet, 1971; 1; 1068, pmid: 4102992
65. Davis VE, Cashaw JL, McMurtrey KD, Disposition of catecholamine-derived alkaloids in mammalian systems: Adv Exp Med Biol, 1975; 59; 65-78, pmid: 1101670
66. Coscia CJ, Burke W, Jamroz G, Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients: Nature, 1977; 269; 617-19, pmid: 917111
67. Cadet P, Zhu W, Mantione K, Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson’s patients: Int J Mol Med, 2003; 12; 485-92, pmid: 12964024
68. Galloway MP, Burke WJ, Coscia CJ, Tetrahydroisoquinolinecarboxylic acids and catecholamine metabolism in adrenal medulla explants: Biochem Pharmacol, 1982; 31; 3251-56, pmid: 7150353
69. Nimit Y, Schulze I, Cashaw JL, Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors: J Neurosci Res, 1983; 10; 175-89, pmid: 6313954
70. Okada T, Shimada S, Sato K, Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells: Neurosci Res, 1998; 30; 87-90, pmid: 9572583
71. Soh Y, Shin MH, Lee JS, Oxidative DNA damage and glioma cell death induced by tetrahydropapaveroline: Mutat Res, 2003; 544; 129-42, pmid: 14644315
72. Shin MH, Jang JH, Surh YJ, Potential roles of NF-kappaB and ERK1/2 in cytoprotection against oxidative cell death induced by tetrahydropapaveroline: Free Radic Biol Med, 2004; 36; 1185-94, pmid: 15082072
73. Kim YM, Kim MN, Lee JJ, Lee MK, Inhibition of dopamine biosynthesis by tetrahydropapaveroline: Neurosci Lett, 2005; 386; 1-4, pmid: 16026929
74. Fricchione GL, Stefano GB, Placebo neural systems: Nitric oxide, morphine and the dopamine brain reward and motivation circuitries: Med Sci Monit, 2005; 11(5); MS54-65, pmid: 15874901
75. Berg D, Becker G, Reiners K, Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica: J Neural Transm, 1999; 106; 725-28, pmid: 10907730
76. Berg D, Becker G, Naumann M, Reiners K, Morphine in tardive and idiopathic dystonia (short communication): J Neural Transm, 2001; 108; 1035-41, pmid: 11716139
77. Donnerer J, Cardinale G, Coffey J, Chemical characterization and regulation of endogenous morphine and codeine in the rat: J Pharmacol Exp Ther, 1987; 242; 583-87, pmid: 3497260
78. Donnerer J, Oka K, Brossi A, Presence and formation of codeine and morphine in the rat: Proc Natl Acad Sci USA, 1986; 83; 4566-67, pmid: 3459191
79. Weitz CJ, Faull KF, Goldstein A, Synthesis of the skeleton of the morphine molecule by mammalian liver: Nature, 1987; 330; 674-77, pmid: 3683586
80. Cardinale GJ, Donnerer J, Finck AD, Morphine and codeine are endogenous components of human cerebrospinal fluid: Life Sci, 1987; 40; 301-6, pmid: 3796227
81. Gintzler AR, Levy A, Spector S, Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide morphine-like compound in the central nervous system: Proc Natl Acad Sci USA, 1976; 73; 2132-36, pmid: 1064881
82. Gintzler AR, Gershon MD, Spector S, A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain: Science, 1978; 199; 447-48, pmid: 339350
83. Luk LY, Bunn S, Liscombe DK, Mechanistic studies on norcoclaurine synthase of benzylisoquinoline alkaloid biosynthesis: an enzymatic Pictet-Spengler reaction: Biochemistry, 2007; 46; 10153-61, pmid: 17696451
84. Stefano GB, Kream RM, Endogenous morphine synthetic pathway preceded and gave rise to catecholamine synthesis in evolution (Review): Int J Mol Med, 2007; 20; 837-41, pmid: 17982691
85. Stefano GB, Bianchi E, Guarna M, Nicotine, alcohol and cocaine coupling to reward processes via endogenous morphine signaling: The dopamine-morphine hypothesis: Med Sci Monit, 2007; 13(6); RA91-102, pmid: 17534245
86. Nasuti C, Gabbianelli R, Falcioni ML, Dopaminergic system modulation, behavioral changes, and oxidative stress after neonatal administration of pyrethroids: Toxicology, 2007; 229; 194-205, pmid: 17140720
87. Stefano GB, Kream RM, Mantione KJ, Ptacek R, Endogenous morphine, stress and psychiatric disorders – review of actual findings: Journal of Czech Psychology, 2012 In Press
88. Kream RM, Stefano GB, Schizophrenia: Comorbidity and/or Self Medication: Biomedical Papers, 2012 In Press
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387